U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900920) titled 'A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia' on March 24.
Brief Summary: This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment.
The study consists of a treatment period and a safety follow-up period.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition: ...